Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Santen Bags Rights to Osmotica’s Droopy Eyelid Drug
Japanese ophthalmology powerhouse Santen Pharmaceutical has acquired exclusive rights to develop and commercialize Osmotica Pharmaceuticals’ ptosis treatment RVL-1201 (oxymetazoline) outside the US including Japan, China, and as well as Europe. Santen and RVL Pharmaceuticals, an ophthalmology subsidiary of Osmotica, said…
To read the full story
Related Article
- Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
December 27, 2024
BUSINESS
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Otsuka’s IgA Drug Voyxact Sees Strong US Uptake: EVP
April 30, 2026
- KM Biologics, India’s Serum Institute Partner on Japanese Encephalitis Vaccine
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…